Document Detail


Effects of sublingual nitroglycerin on human uterine contractility during the active phase of labor.
MedLine Citation:
PMID:  12114917     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Nitroglycerin is administered intravenously in acute obstetric emergencies to relax the uterus. However, complications (eg, hypotension, acute uterine bleeding) are frequent, which prompted a search for alternative routes of administration. We hypothesized that the sublingual administration of nitroglycerin would reduce uterine tone and contractility with few complications. Intrauterine pressure was measured in 12 women who were actively laboring (>4 cm dilatation, regular contractions) with epidural analgesia and who were alert and responsive throughout the study. In a double-blind fashion, subjects were randomized to receive either placebo or sublingual nitroglycerin (3 doses, 800 microg each) 10 minutes apart. The obstetric anesthesiologist continuously monitored maternal blood pressure and fetal heart rate. Cervical dilatation was assessed at the beginning and the end of the protocol. The area under the intrauterine pressure curve (integral) was used to estimate uterine contractility. Intrauterine pressure was analyzed before the randomization code was broken. Nitroglycerin did not alter the intrauterine pressure integral after the first dose (placebo, 3147 mm Hg x s [95% CI, 2206-4088] vs nitroglycerin, 4146 mm Hg x s [95% CI, 2451-5841]; P =.22), second dose (placebo, 3123 mm Hg x s [95% CI, 2447-3799] vs nitroglycerin, 3611 mm Hg x s [95% CI, 2723-4499]; P =.28), or third dose (placebo, 3303 mm Hg x s [95% CI, 2616-3990] vs nitroglycerin, 3810 mm Hg x s [95% CI, 2306-5314]; P =.45). Cervical dilation, basal uterine tone, duration and frequency of uterine contractions, or fetal heart rhythm remained unaffected. Maternal mean arterial pressure decreased significantly after nitroglycerin was administered. All women were delivered vaginally without intervention. Three doses of sublingual nitroglycerin (800 microg per dose) reduce neither uterine activity nor tone, despite lowering maternal blood pressure. If a clinical option, sublingual nitroglycerin will require a higher dose, which would place mother and fetus at risk for complication.
Authors:
Catalin S Buhimschi; Irina A Buhimschi; Andrew M Malinow; Carl P Weiner
Related Documents :
22622667 - Density functional theory study of high-pressure effect on crystalline 4,4',6,6'-tetra(...
17572927 - Progressive fetal atrioventricular block in heterotaxy syndrome.
24216057 - Osteoarthritis bone marrow lesions at the knee and large artery characteristics.
16289267 - Fetal infusions of plasma cause an increase in umbilical vascular resistance in sheep.
3750597 - Percutaneous intrapelvic pressure registration in patients with ureterointestinal urina...
11744637 - Blood pressure and mesenteric resistance arterial function after spaceflight.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  187     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-07-12     Completed Date:  2002-08-01     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  235-8     Citation Subset:  AIM; IM    
Affiliation:
Department of Obstetrics, Gynecology and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, USA. cbuhimsc@med.wayne.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Sublingual
Adult
Double-Blind Method
Female
Humans
Labor, Obstetric / drug effects
Multivariate Analysis
Nitroglycerin / pharmacology*
Pregnancy
Pressure
Uterine Contraction / drug effects*
Uterus / drug effects
Chemical
Reg. No./Substance:
55-63-0/Nitroglycerin
Comments/Corrections
Erratum In:
Am J Obstet Gynecol 2002 Aug;187(2):411

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of a case of primary retroperitoneal mucinous cystadenocarcinoma: is adjuvant hysterectomy...
Next Document:  Case report and review of the perinatal implications of maternal lithium use.